[go: up one dir, main page]

LT4515B - Būdas apsaugoti odą nuo senėjimo veikiant šviesai - Google Patents

Būdas apsaugoti odą nuo senėjimo veikiant šviesai Download PDF

Info

Publication number
LT4515B
LT4515B LT98-091A LT98091A LT4515B LT 4515 B LT4515 B LT 4515B LT 98091 A LT98091 A LT 98091A LT 4515 B LT4515 B LT 4515B
Authority
LT
Lithuania
Prior art keywords
uvb
skin
inhibitor
mmp
inhibits
Prior art date
Application number
LT98-091A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT98091A (en
Inventor
John J. Voorhees
Gary J. Fisher
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24355242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4515(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Publication of LT98091A publication Critical patent/LT98091A/xx
Publication of LT4515B publication Critical patent/LT4515B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
LT98-091A 1996-01-19 1998-07-09 Būdas apsaugoti odą nuo senėjimo veikiant šviesai LT4515B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/588,771 US5837224A (en) 1996-01-19 1996-01-19 Method of inhibiting photoaging of skin

Publications (2)

Publication Number Publication Date
LT98091A LT98091A (en) 1999-02-25
LT4515B true LT4515B (lt) 1999-06-25

Family

ID=24355242

Family Applications (1)

Application Number Title Priority Date Filing Date
LT98-091A LT4515B (lt) 1996-01-19 1998-07-09 Būdas apsaugoti odą nuo senėjimo veikiant šviesai

Country Status (20)

Country Link
US (1) US5837224A (es)
EP (1) EP0883398A4 (es)
JP (1) JP3705820B2 (es)
CN (1) CN1086937C (es)
AR (1) AR005650A1 (es)
BR (1) BR9707018A (es)
CA (1) CA2241981C (es)
CO (1) CO4770951A1 (es)
CZ (1) CZ291530B6 (es)
EE (1) EE9800216A (es)
HU (1) HUP9900655A3 (es)
LT (1) LT4515B (es)
MY (1) MY119711A (es)
NO (1) NO983019L (es)
NZ (1) NZ330860A (es)
PL (1) PL327827A1 (es)
SI (1) SI9720015A (es)
SK (1) SK95998A3 (es)
TR (1) TR199801376T2 (es)
WO (1) WO1997025969A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
KR19990072009A (ko) * 1995-08-12 1999-09-27 게리 이. 프리드만 메탈로프로티나제 방해제, 그를 포함하는 약제 조성물 및 약제로서의 용도, 그리고 그의 제조방법 및 제조에 유용한 중간체
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
CN100360121C (zh) * 1997-02-25 2008-01-09 密执安州立大学董事会 防护和处理人皮肤经时性衰老的方法和组合物
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US20050058709A1 (en) * 1997-06-04 2005-03-17 Fisher Gary J. Methods for inhibiting photoaging of human skin using orally-administered agent
TWI234467B (en) * 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
JP3973748B2 (ja) * 1998-01-14 2007-09-12 花王株式会社 発毛抑制剤
US6683069B1 (en) * 1998-04-02 2004-01-27 Regents Of The University Of Michigan Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin
FR2777186B1 (fr) * 1998-04-10 2001-03-09 Oreal Utilisation d'au moins un hydroxystilbene dans une composition raffermissante
FR2777183B1 (fr) * 1998-04-10 2001-03-02 Oreal Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
US20060212025A1 (en) 1998-11-30 2006-09-21 Light Bioscience, Llc Method and apparatus for acne treatment
US6283956B1 (en) * 1998-11-30 2001-09-04 David H. McDaniels Reduction, elimination, or stimulation of hair growth
US6887260B1 (en) 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US9192780B2 (en) 1998-11-30 2015-11-24 L'oreal Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
WO2000051562A1 (fr) * 1999-03-03 2000-09-08 Shiseido Company, Ltd. Inhibiteur des metalloproteases matricielles et utilisation associee
AU4064100A (en) * 1999-04-01 2000-10-23 Board Of Trustees Of The University Of Arkansas, The P38mapk inhibitor and uses thereof
US7268148B2 (en) * 1999-05-20 2007-09-11 Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
US20040235950A1 (en) * 1999-05-20 2004-11-25 Voorhees John J. Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
WO2001005430A1 (en) * 1999-07-20 2001-01-25 Merck & Co., Inc. Sustained release drug dispersion delivery device
US6982284B1 (en) 1999-09-10 2006-01-03 Applied Genetics Incorporated Dermatics Compositions and methods for modification of skin lipid content
DE19955349A1 (de) * 1999-11-17 2001-08-02 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
JP4074043B2 (ja) * 2000-03-27 2008-04-09 株式会社資生堂 皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法
DE10020447A1 (de) * 2000-03-31 2001-10-11 Henkel Kgaa Verwendung von Protease-Inhibitoren in der Kosmetik und Pharmazie
AU2001272028A1 (en) * 2000-06-26 2002-01-08 The Regents Of The University Of Michigan Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
AU2001273115C1 (en) * 2000-06-29 2009-03-26 Quick Med Technologies, Inc. Cosmetic composition and method
US20040185127A1 (en) * 2001-06-29 2004-09-23 Lerner David S. Cosmetic composition and method
AU2001271889A1 (en) 2000-07-06 2002-01-21 The Regents Of The University Of Michigan UVA (>360-400) and UVB Specific Sunscreens
FR2811561B1 (fr) * 2000-07-13 2003-03-21 Oreal Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase
FR2811563B1 (fr) * 2000-07-13 2003-06-20 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive, et au moins un compose augmentant la synthese des glycosaminoglycanes
US20020119107A1 (en) * 2000-12-18 2002-08-29 James Varani Method for protecting and restoring skin using selective MMP inhibitors
DE10102784A1 (de) * 2001-01-22 2002-08-01 Henkel Kgaa Kosmetische oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes
JP2002277455A (ja) * 2001-03-15 2002-09-25 Shiseido Co Ltd 皮膚老化因子検出組成物及び検出方法
JP4575667B2 (ja) 2002-03-08 2010-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬として有用な大環状化合物
US7354956B2 (en) * 2002-04-12 2008-04-08 L'oreal Composition containing a sapogenin and use thereof
US20050202001A1 (en) * 2002-04-24 2005-09-15 Han-Mo Koo Enhancement of human epidermal melanogenesis
CN101564440B (zh) * 2002-06-25 2012-04-18 株式会社资生堂 抗老化剂
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
BRPI0313155B8 (pt) 2002-07-29 2021-05-25 Cardax Pharmaceuticals Inc composto químico derivado ou análogo de carotenóide, composição farmacêutica, e, uso do composto
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
CA2531099A1 (en) 2003-04-10 2004-10-28 Light Bioscience, Llc Photomodulation methods and devices for regulating cell proliferation and gene expression
JP4739202B2 (ja) 2003-07-31 2011-08-03 ジェントルウェイブス エルエルシー 熱傷、創傷、および関連皮膚疾患の光力学治療のためのシステムおよび方法
FR2858932B1 (fr) * 2003-08-22 2009-10-30 Oreal Composition destinee a lutter contre la degradation des fibres de collagene induite en condition d'exposition solaire naturelle
US20050058611A1 (en) * 2003-08-22 2005-03-17 L'oreal Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
WO2005095959A2 (en) * 2004-03-29 2005-10-13 Howard Murad Methods for treating dermatological conditions in a patient
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US20060265030A1 (en) * 2004-11-12 2006-11-23 Light Bioscience, Llc System and method for photodynamic cell therapy
US8008093B2 (en) * 2004-12-02 2011-08-30 The University Of North Carolina At Chapel Hill Inhibition of Hsp27 phosphorylation for the treatment of blistering disorders
WO2007064871A2 (en) * 2005-12-02 2007-06-07 Howard Murad Diagnostic and treatment regimen for achieving body water homeostasis
US7642402B2 (en) * 2005-12-20 2010-01-05 Kao Corporation Human photoaged skin model
US8771647B2 (en) * 2005-12-20 2014-07-08 Kao Corporation Human photoaged skin model
US20090220436A1 (en) * 2006-05-11 2009-09-03 Living Proof, Inc. In situ polymerization for skin treatment
KR100879558B1 (ko) * 2007-07-31 2009-01-22 라이브켐 주식회사 디벤조­파라­디옥신 유도체를 유효성분으로 함유한 피부보호 및 개선제
WO2009121168A1 (en) * 2008-04-01 2009-10-08 Biopharmacopae Design International Inc. Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection
CA2720664A1 (fr) * 2008-04-22 2009-11-26 Centre National De La Recherche Scientifique Nouvelles compositions inhibant la melanogenese et leurs utilisations
US8609075B2 (en) 2009-09-30 2013-12-17 Shiseido Company, Ltd. Heparanase activity inhibitor
CN102573819A (zh) 2009-09-30 2012-07-11 株式会社资生堂 乙酰肝素酶活性抑制剂以及含有该乙酰肝素酶活性抑制剂的皱纹改善剂和药物组合物
US8435541B2 (en) 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
US10267796B2 (en) * 2010-10-25 2019-04-23 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
CN105101979B (zh) 2012-12-21 2021-10-08 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
JP2015221768A (ja) * 2014-05-23 2015-12-10 日本メナード化粧品株式会社 皮膚外用剤または内用剤
JP2016216435A (ja) * 2015-05-18 2016-12-22 共栄化学工業株式会社 評価方法
JP6157659B1 (ja) * 2016-02-10 2017-07-05 イノレックス インベストメント コーポレイション 紫外線誘発性脂質過酸化を低減する相乗的組成物、配合物及び関連の方法
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
CN112263529A (zh) * 2020-10-27 2021-01-26 圣菲之美（湖北）生物科技有限公司 一种抗衰老组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603146A (en) * 1984-05-16 1986-07-29 Kligman Albert M Methods for retarding the effects of aging of the skin
US5019569A (en) * 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
EP0357646B1 (en) * 1987-04-06 1995-03-22 Daltex Medical Sciences, Inc. Treatment of aged skin with oral 13-cis-retinoic acid
US4994491A (en) * 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
AU636595B2 (en) * 1989-01-19 1993-05-06 Ortho Pharmaceutical Corporation Method for the treatment or prevention of intrinsically aged skin with retinoids
US5002760A (en) * 1989-10-02 1991-03-26 Katzev Phillip K Retinol skin care composition
US5051449A (en) * 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
JPH07501540A (ja) * 1991-11-25 1995-02-16 リチャードソン、ビックス、インコーポレーテッド 皮膚シワ及び／又は皮膚萎縮を調節するための組成物
GR1002207B (en) * 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
CA2212127A1 (en) * 1995-02-03 1996-08-08 Cosmederm Technologies Formulations and methods for reducing skin irritation
DE69632255T3 (de) * 1995-06-08 2010-05-20 Johnson & Johnson Consumer Companies, Inc. Sonnenschutzmittel
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
1442- ET AL.: "Wlaschek M, Heinen G, Poswig A, Schwarz A, Krieg T, Scharffetter-Kochanek KUVA-induced autocrine stimulation of fibroblast-derived collagenase/MMP-1 by interrelated loops of interleukin-1 and interleukin-6", PHOTOCHEM. PHOTOBIOL., 1994, pages 550 - 556
ANDREA FANJUL ET AL.: "A new class of retinoids with selective inhibition of AP-1 inhibits proliferation", NATURE, 1994, pages 107 - 111
ANGEL P ET AL.: "Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor", CELL, 1987, pages 729 - 739, XP027461475, DOI: doi:10.1016/0092-8674(87)90611-8
DEVARY Y, ROSETTE C, DIDONATO JA, KARIN M.: "NF-kappa B activation by ultraviolet light not dependent on a nuclear signal", SCIENCE, 1993, pages 1442 - 1445, XP002993561, DOI: doi:10.1126/science.8367725
EDWARD M. JACKSON, PHD.: "Substantiating the Safety of Fragrances and Fragranced Products", COSMETICS AND TOILETRIES, 1993, pages 43 - 56
HILL PA ET AL.: "Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase", BIOCHEM J., 1995, pages 167 - 175
J G CONWAY ET AL.: "Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor", J EXP MED., 1995, pages 449 - 457, XP000574663, DOI: doi:10.1084/jem.182.2.449
JOHN HODGSON: "Matrix metalloproteinase inhibitors will be approved as drugs, probably this year, but questions remain concerning their specificity, bioavailability, and potential long-term toxicity", NATURE BIOTECHNOLOGY, 1995, pages 554 - 557
MAUCH C, KRIEG T, BAUER EA.: "Role of the extracellular matrix in the degradation of connective tissue", ARCH DERMATOL RES., 1994, pages 107 - 114
R. G. F. MURRAYET AL.: "Bergeys Manual of Systematic Bacteriology"
SATO H, SEIKI M.: "Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells", ONCOGENE, 1993, pages 395 - 405

Also Published As

Publication number Publication date
EP0883398A1 (en) 1998-12-16
NZ330860A (en) 1999-11-29
EE9800216A (et) 1999-04-15
CA2241981A1 (en) 1997-07-24
LT98091A (en) 1999-02-25
CZ291530B6 (cs) 2003-03-12
TR199801376T2 (xx) 1998-10-21
NO983019D0 (no) 1998-06-29
CN1086937C (zh) 2002-07-03
SK95998A3 (en) 1999-01-11
AU701132B2 (en) 1999-01-21
HK1018885A1 (en) 2000-01-07
AU1831797A (en) 1997-08-11
HUP9900655A1 (hu) 1999-07-28
SI9720015A (sl) 1999-10-31
AR005650A1 (es) 1999-07-14
CO4770951A1 (es) 1999-04-30
CZ225898A3 (cs) 1998-10-14
CA2241981C (en) 2002-03-19
BR9707018A (pt) 1999-07-20
PL327827A1 (en) 1999-01-04
WO1997025969A1 (en) 1997-07-24
JP2000503660A (ja) 2000-03-28
JP3705820B2 (ja) 2005-10-12
MY119711A (en) 2005-07-29
NO983019L (no) 1998-08-19
EP0883398A4 (en) 1999-05-12
HUP9900655A3 (en) 2000-09-28
CN1211178A (zh) 1999-03-17
US5837224A (en) 1998-11-17

Similar Documents

Publication Publication Date Title
LT4515B (lt) Būdas apsaugoti odą nuo senėjimo veikiant šviesai
AU737376B2 (en) Methods and compositions for preventing and treating chronological aging in human skin
CA2601462C (en) Compositions and methods for inhibiting photoaging of skin
KR20010042422A (ko) 인간 피부에서의 콜라젠 합성의 ｕｖ-유도 억제를감소시키는 방법 및 그 용도의 조성물
AU701132C (en) Method of inhibiting photoaging of skin
KR100352687B1 (ko) 광노화를예방하기위한화장품
HK1018885B (en) Method of inhibiting photoaging of skin
Riccardi Reversal of photoaging of the skin by topical d-alpha tocopherol, ascorbic acid, and L-selenomethionine: A comparative analysis performed by light and transmission electron microscopy
Soter Acute Effects of Ultraviolet Radiation
MXPA99007883A (es) Metodos y composiciones para prevernir y tratar el envejecimiento cronológico en la piel humana
MXPA99011052A (es) Composiciones y metodos para inhibir el fotoenvejecimiento de la piel

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20000117